

Atty Dkt. No.: IRVN-005CIP  
USSN: 09/771,263

### AMENDMENTS TO THE SPECIFICATION

**Replace the paragraph beginning at page 10, line 17 with the following:**

A key difference is the alloantigens that the lymphocytes in the composition have been activated against. In WO 96/29394, the lymphocytes are activated using leukocytes of the patient to be treated, and are therefore primed specifically against the ~~antigens~~ *alloantigens* of the patient. In the present invention, the lymphocytes are activated against ~~alloantigens~~ *alloantigens of a second unrelated donor*. The donor is invariably allogeneic to the patient at a number of loci for both class I and class II histocompatibility antigens. As a consequence, the lymphocytes are typically not primed specifically against alloantigens of the intended recipient.

**Replace the paragraph beginning at page 11, line 26 with the following:**

"Mixed lymphocyte reaction", "mixed lymphocyte culture", "MLR", and "MLC" are used ~~interchangeably~~ *interchangeably* to refer to a mixture comprising a minimum of two different cell populations that are allotypically different. At least one of the allotypically different cells is a lymphocyte. The cells are cultured together for a time and under suitable conditions to result in the stimulation of the lymphocytes. A frequent objective of an MLC is to provide allogeneic stimulation such as may *initiate* proliferation of the lymphocytes; but unless indicated, proliferation during the culture is not required. In the proper context, these terms may alternatively refer to a mixture of cells derived from such a culture. When cells from an MLC are administered as a bolus to a human, especially in a tumor bed, it is referred to as a "cytoimplant@".

**Replace the paragraph beginning at page 14, line 23 with the following:**

There are a number of animal models for cancer that can be used to test and adjust the compositions and methods of this invention, if desired. Certain models involve injecting in-bred animals with established syngeneic tumor lines. The tumors can be co-injected with a potentially therapeutic composition, allowed to establish before therapy is commenced, or administered as a challenge at some time following *vaccination* of a naive animal. Illustrations are provided in the ~~Example~~ *Examples* section. Also useful

Atty Dkt. No.: IRVN-005CIP  
USSN: 09/771,263

are chimeric animal models, described in U.S. Patent Nos. 5,663,481, 5,602,305 and 5,476,993; EP application 379,554; and PCT Publication No. WO 91/01760.

**Replace the paragraph beginning at page 19, line 4 with the following:**

Since cytokine secretion is believed to play an important role in eliciting the response in the treated subject, cytokines can be tested in a standard ~~immunoassay~~, immunoassay. Particular cytokines of interest are IL-2, IL-4, IL-6, TNF- $\alpha$ , LT, IFN- $\gamma$ , G-CSF, M-CSF (both membrane and secreted form), and GM-CSF. For example, particular degrees of stimulation is indicated by levels of biological activity of TNF- $\alpha$  or LT at 50-150 U/mL, or 500-3500 pg/mL.